CAS: 61337-89-1; 2-(4-Methyl-2-Phenyl-1-Piperazinyl)-3-Pyridinemethanol

该化合物是一种属于管道衍生物类别的化学化合物,具有六人组成的环状管子核心,内含两个氮原子,代之以一个环环状和苯基组的氢氧化甲基组;氢氧甲基组的存在表明氢联结的潜力,这可能影响其溶解性和再活动;甲基和苯基子子子组群可能助长其亲脂性,有可能影响其生物活动和药用植物特性;该化合物可能展示各种生物活动,使其对医药化学和药物开发感兴趣;其结构特征表明它可能与生物目标相互作用,可能影响...

结构式图片

相似化合物

61338-13-4 191546-94-8 61337-88-0

欧盟法规

REACH注册ECHA物质C&L通报

上下游产品

CAS号61338-13-4 米氮平酸 | CAS号61337-88-0 1-(3-氰基吡啶-2)-2-... | CAS号6602-54-6 2-氯烟腈 | CAS号5271-27-2 1-甲基-3-苯基哌嗪 | CAS号24219-97-4 米安舍林 | CAS号85650-52-8 米氮平

合成工艺路线路线简述

    2-氨基烟酸乙酯置于甲醇,Sodium Tetrahydroborate,Sodium Iodide体系中,用 四氢呋喃,乙醇,氯仿,水,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 19.75H,反应生成 2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇
    参考文献:一种米氮醇的合成方法
    标题:一种米氮醇的合成方法
    摘要:本发明公开了一种米氮醇的合成方法,是将n‑(2‑氯乙基)‑n‑甲基‑α‑氯‑β‑苯乙胺溶解在非极性溶剂与水的混合溶液中得到溶液a,2‑氨基‑3‑羟甲基吡啶溶解在含少量低碳醇的非极性溶剂中得到溶液b,将溶液b滴加到溶液a中反应得到的中间体溶解在无水高沸点极性溶剂中,惰性气体保护下滴加到无机碘化物的无水高沸点极性溶剂中,反应得到米氮醇.本发明方法将合成米氮醇的步骤拆分成两步,特定的溶剂体系避免了中间体直接高温反应被氧化,提高了反应的稳定性和收率.

    海关参考信息

    专利信息


    专利号:US-6852855-B2
    优先权日:1999-04-19
    标 题 :Synthesis of piperazine ring
    发明人:DOLITZKY BEN-ZION
    权利人:TEVA PHARMA
    摘要:A novel process for preparing a compound of the formula I: n n nwhereinn nR 1 denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy or arylalkoxy; R 2 denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy, arylalkoxy, tosyl, formyl, acetyl or amine; and R 3 denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy or arylalkoxy is disclosed. These compounds are useful in the synthesis of the antidepressant mirtazapine and other tetracyclic compounds.

    专利号:US-6603003-B2
    优先权日:2000-11-07
    标 题 :Method for the preparation of piperazine and its derivatives
    发明人:SEBASTIAN SONNY; PATEL HETAL VIRENDRA; THENNATI RAJAMANNAR
    权利人:SUN PHARMACEUTICAL IND LTD
    摘要:A novel method for the synthesis of piperazine and its derivatives of formula 1,wherein R is selected from hydrogen, or a lower alkyl group having 1 to 6 carbon atoms or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms;R1 is selected from hydrogen, a methyl group, a phenyl group optionally substituted with an alkyl group having 1 to 6 carbon atoms, or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; andR2 is selected from hydrogen, or a methyl group, or a fluoromethyl group;comprising the steps:a. reacting an ester of formula 11 with substituted or unsubstituted ethylenediamine of formula 7 to give 3,4-dehydropiperazine-2-one and its derivatives of formula 12, wherein R, R1, R2 are as defined above and R6 is a C1 to C4 linear or branched alkyl group; andb. reacting the 3,4-dehydro-piperazine-2-one and its derivatives of formula 12 with a reducing agent to yield the piperazine and its derivatives of formula 1.

    专利号:US-2003069417-A1
    优先权日:1999-04-19
    标题:Novel synthesis and crystallization of piperazine ring-containing compounds
    发明人:SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
    摘要:The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine may be made of hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130° C. The method of the present invention also includes reacting 2-amino-3-hydroxymethyl pyridine with N-methyl-1-phenyl-2,2′-iminodiethyl chloride to form 1-(3-hydroxymethylpyridyl-2)-4-methyl-2-phenyl piperazine, and adding sulfuric acid to the 1-(3-hydroxymethylpyridyl-2)-phenyl-4-methylpiperazine to form mirtazapine. The present invention a recrystallization of mirtazapine from crude mirtazapine. The present invention also relates to crystalline adducts of mirtazapine and water, preferably containing up to about 3.5% by weight water, pharmaceutical compositions containing the crystalline adducts, and methods of treating depression by administering such compositions.

    专利号:US-2002035256-A1
    优先权日:1999-04-19
    标题:Novel synthesis of piperazine ring

    专利号:WO-0062782-A1
    优先权日:1999-04-19
    标题 :Novel synthesis and crystallization of piperazine ring-containing compounds
    发明人:SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
    权利人:TEVA PHARMA; TEVA PHARMA; SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
    摘要:The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridly-2)-4-methyl-2-phenyl-piperazine may be made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130 °C. The method of the present invention also includes reacting 2-amino-3-hydroxymethyl pyridine with N-methyl-1-phenyl-2, 2'-iminodiethyl chloride to form 1-(3-hydroxymethylpyridyl-2)-4-methyl-2-phenyl piperazine, and adding sulfuric acid to the 1-(3-hydroxymethylpyridyl-2)-phenyl-4-methylpiperazine to form mirtazapine. The present invention also relates to new processes for recrystallization of mirtazapine form crude mirtazapine.

    专利号:US-6576764-B2
    优先权日:1999-04-19
    标 题:Synthesis and crystallization of piperazine ring-containing compounds
    发明人:SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
    权利人:TEVA PHARMA
    摘要:The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine may be made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130° C. The method of the present invention also includes reacting 2-amino-3-hydroxymethyl pyridine with N-methyl-1-phenyl-2,2'-iminodiethyl chloride to form 1-(3-hydroxymethylpyridyl-2)-4-methyl-2-phenyl piperazine, and adding sulfuric acid to the 1-(3-hydroxymethylpyridyl-2)-phenyl-4-methylpiperazine to form mirtazapine. The present invention also relates to new processes for recrystallization of mirtazapine from crude mirtazapine.
    浙江燎原药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.liaoyuan.com.cn
    企业联系电话:86-576-85300990,85308861,85300959👤
    📞浙江燎原药业有限公司 ⚠️参考联系方式
    联系人:张鹏
    电话:86-576-85300990,85308861,85300959

    传真:86-576-85302808
    邮箱:alanzp@liaoyuan.com.cn
    通信地址: 浙江省临海市靖江花城9号楼3F
    邮编: 317000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省临海市靖江花城9号楼3F
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海巍涛化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.witofly.com
    企业联系电话:021-50630626,17717886015👤
    📞上海巍涛化工有限公司 ⚠️参考联系方式
    联系人:销售部
    电话:021-50630626,17717886015
    手机:17717886015
    传真:021-50563898
    邮箱:sales@witofly.com
    通信地址: 上海市松江区沈砖公路5808号14幢5层536A室
    邮编: 200127
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海市松江区沈砖公路5808号14幢5层536A室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    苏州恒益医药原料有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.szhengyi.com
    企业联系电话:0512-57663281;18913251393👤
    📞苏州恒益医药原料有限公司 ⚠️参考联系方式
    联系人:王经理
    电话:0512-57663281;18913251393
    手机:18913251393
    传真:0512-57665666
    邮箱:18913251393@189.cn
    通信地址: 江苏省太仓市城厢镇上海东路188号 万达广场写字楼B座706室
    邮编: 215400
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省太仓市城厢镇上海东路188号 万达广场写字楼B座706室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知